Regulation of Intestinal Epithelial Tight Junction Barrier

肠上皮紧密连接屏障的调节

基本信息

  • 批准号:
    8141671
  • 负责人:
  • 金额:
    --
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2011
  • 资助国家:
    美国
  • 起止时间:
    2011-04-01 至 2016-09-30
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): Abstract Defective intestinal epithelial tight junction (TJ) barrier has been postulated to be a key pathogenic factor in variety of inflammatory diseases of the gut (including Crohn's disease, ulcerative colitis, necrotizing enterocolitis, NSAID associated enteritis, and infectious diarrheal syndromes) and systemic inflammatory conditions (including alcoholic liver disease, heat stroke, hemorrhagic shock, and critically ill). The defective intestinal TJ barrier allows paracellular permeation of luminal antigens across the epithelial barrier, leading to both local inflammatory response in the gut and systemic circulation of bacterial endotoxins culminating in systemic inflammatory response and end-organ damage. Although gut-derived lipopolysaccharides play a critical role in the pathogenesis of intestinal inflammation and systemic inflammatory response, their role in disruption of intestinal epithelial tight junction barrier remains unknown. Our preliminary studies indicated that lipopolysaccharide (LPS) at physiologically relevant concentrations (.1 to 1 ng/ml) causes an increase in intestinal epithelial TJ permeability, unrelated to apoptosis or cell death. The broad objectives of this grant proposal are to elucidate the intracellular and molecular mechanisms that mediate the LPS induced increase in intestinal TJ permeability using an-in-vitro (consisting of filter-grown Caco-2 intestinal epithelial monolayers) and in-vivo (re-cycling intestinal perfusion) murine model systems. Our preliminary data suggested that the LPS induced increase in intestinal epithelial TJ permeability was mediated in part by: 1) increase in Toll-like receptor-4 (TLR-4) expression; 2) activation of p38 kinase pathway; and 3) increase in myosin light chain kinase (MLCK) mRNA and protein expression. Based on our preliminary studies, we hypothesize that physiologically relevant concentrations of LPS induce an increase in intestinal epithelial TJ permeability via TLR-4 signal transduction cascade activation of MLCK gene and MLCK-regulated opening of the intestinal epithelial TJ barrier. The proposed specific aims are to: 1) delineate the involvement of TLR-4 signal transduction cascade in LPS induced increase in intestinal epithelial TJ permeability; 2) delineate the molecular processes involved in LPS induced increase in intestinal TJ permeability; and 3) delineate the mechanisms involved in LPS induced increase in intestinal permeability in-vivo. PUBLIC HEALTH RELEVANCE: Narrative Defective intestinal barrier or "leaky gut" allows bacterial antigens in the gut to be absorbed and induce inflammatory response. In wide variety of diseases, absorbed bacterial antigens reach systemic circulation and induce systemic inflammatory reaction, leading to multi-organ failure or death. Gut- derived bacterial antigens are important mediators of intestinal and systemic inflammatory response. The purpose of this grant application is to elucidate the pathogenic mechanisms involved in bacterial antigen induced disruption of intestinal barrier (or development of leaky gut).
描述(由申请人提供): 摘要 肠上皮紧密连接(TJ)屏障缺陷被认为是多种肠道炎症性疾病(包括克罗恩病、溃疡性结肠炎、坏死性小肠结肠炎、NSAID相关性肠炎和感染性腹泻综合征)和全身炎症的关键致病因素。状况(包括酒精性肝病、中暑、失血性休克和危重病)。有缺陷的肠道 TJ 屏障允许管腔抗原穿过上皮屏障进行细胞旁渗透,导致肠道局部炎症反应和细菌内毒素的全身循环,最终导致全身炎症反应和终末器官损伤。尽管肠源性脂多糖在肠道炎症和全身炎症反应的发病机制中发挥着关键作用,但它们在破坏肠上皮紧密连接屏障中的作用仍然未知。我们的初步研究表明,生理相关浓度(0.1 至 1 ng/ml)的脂多糖 (LPS) 会导致肠上皮 TJ 通透性增加,与细胞凋亡或细胞死亡无关。该拨款提案的主要目标是阐明使用体外(由过滤生长的 Caco-2 肠上皮单层组成)和体内(重新制备)介导 LPS 诱导肠道 TJ 通透性增加的细胞内和分子机制。 -循环肠道灌注)鼠模型系统。我们的初步数据表明,LPS 诱导的肠上皮 TJ 通透性增加部分是通过以下介导的:1) Toll 样受体 4 (TLR-4) 表达的增加; 2)p38激酶途径的激活; 3) 肌球蛋白轻链激酶 (MLCK) mRNA 和蛋白表达增加。根据我们的初步研究,我们假设生理相关浓度的 LPS 通过 TLR-4 信号转导级联激活 MLCK 基因和 MLCK 调节的肠上皮 TJ 屏障打开,诱导肠上皮 TJ 通透性增加。所提出的具体目标是: 1) 阐明 TLR-4 信号转导级联在 LPS 诱导肠上皮 TJ 通透性增加中的作用; 2) 描述 LPS 诱导肠道 TJ 通透性增加所涉及的分子过程; 3) 描述 LPS 诱导体内肠道通透性增加的机制。 公共卫生相关性: 叙述 有缺陷的肠道屏障或“肠漏”会使肠道中的细菌抗原被吸收并诱发炎症反应。在多种疾病中,吸收的细菌抗原到达体循环并诱发全身炎症反应,导致多器官衰竭或死亡。肠道来源的细菌抗原是肠道和全身炎症反应的重要介质。该拨款申请的目的是阐明细菌抗原诱导的肠道屏障破坏(或肠漏的发展)涉及的致病机制。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

THOMAS Y MA其他文献

THOMAS Y MA的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('THOMAS Y MA', 18)}}的其他基金

Intestinal Barrier, Probiotic Bacteria, and the Gut-Liver Axis
肠道屏障、益生菌和肠-肝轴
  • 批准号:
    10316171
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Intestinal Barrier, Probiotic Bacteria, and the Gut-Liver Axis
肠道屏障、益生菌和肠-肝轴
  • 批准号:
    10543991
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Intestinal Barrier, Probiotic Bacteria, and the Gut-Liver Axis
肠道屏障、益生菌和肠-肝轴
  • 批准号:
    9895788
  • 财政年份:
    2019
  • 资助金额:
    --
  • 项目类别:
Bifidobacterium bifidum modulation of intestinal barrier and intestinal inflammation
双歧杆菌对肠道屏障和肠道炎症的调节
  • 批准号:
    9751834
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Bifidobacterium bifidum modulation of intestinal barrier and intestinal inflammation
双歧杆菌对肠道屏障和肠道炎症的调节
  • 批准号:
    9682782
  • 财政年份:
    2018
  • 资助金额:
    --
  • 项目类别:
Regulation of Intestinal Epithelial Tight Junction Barrier
肠上皮紧密连接屏障的调节
  • 批准号:
    8244940
  • 财政年份:
    2011
  • 资助金额:
    --
  • 项目类别:
Interleukin-1 Beta Modulation of Intestinal Tight Junction Barrier
Interleukin-1 Beta 调节肠道紧密连接屏障
  • 批准号:
    7806656
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Interleukin-1 Beta Modulation of Intestinal Tight Junction Barrier
Interleukin-1 Beta 调节肠道紧密连接屏障
  • 批准号:
    8098031
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Interleukin-1 Beta Modulation of Intestinal Tight Junction Barrier
Interleukin-1 Beta 调节肠道紧密连接屏障
  • 批准号:
    7650889
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:
Interleukin-1 Beta Modulation of Intestinal Tight Junction Barrier
Interleukin-1 Beta 调节肠道紧密连接屏障
  • 批准号:
    8290490
  • 财政年份:
    2009
  • 资助金额:
    --
  • 项目类别:

相似国自然基金

东北刺人参不定根提取物基于肠肝轴促进脂质代谢改善酒精性肝病的机制研究
  • 批准号:
    82304841
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
DJ-1抑制AMPK促进肠道屏障稳态失调在非酒精性脂肪性肝病中的作用机制研究
  • 批准号:
    82370582
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
CBX2通过调控AMPK信号通路在非酒精性脂肪肝病发生中的作用和机制研究
  • 批准号:
    82370878
  • 批准年份:
    2023
  • 资助金额:
    48 万元
  • 项目类别:
    面上项目
可溶性LGALS3BP通过GAL-1/Akt调控酒精性肝病的研究
  • 批准号:
    82370599
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
从AMPK调控线粒体裂变和融合研究金钗石斛总生物碱抗非酒精性脂肪肝病的分子机制
  • 批准号:
    82360808
  • 批准年份:
    2023
  • 资助金额:
    32 万元
  • 项目类别:
    地区科学基金项目

相似海外基金

Mechanisms linking the Branched-Chain alpha-Keto Acid regulatory network to the pathogenesis of NASH
支链 α-酮酸调节网络与 NASH 发病机制的联系机制
  • 批准号:
    10628663
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Role of the ubiquitin E3 ligase HUWE1 in age-associated nonalcoholic fatty liver disease
泛素 E3 连接酶 HUWE1 在年龄相关性非酒精性脂肪肝中的作用
  • 批准号:
    10648621
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Alcohol Promotes Hepatitis B Progression by Impairment of Innate Immunity in Liver Cells
酒精通过损害肝细胞的先天免疫促进乙型肝炎的进展
  • 批准号:
    10526257
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Hepatic lymphatics in alcohol-associated liver disease
酒精相关性肝病中的肝淋巴管
  • 批准号:
    10824029
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Goblet cells and intestinal immune response in alcohol-associated liver disease
酒精相关性肝病中的杯状细胞和肠道免疫反应
  • 批准号:
    10446819
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了